Thomas Boettger

Thomas Boettger

Auto-generated profile, based on publicly available information

Thomas Boettger

Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2012 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
EHEduard Hergenreider
Eduard Hergenreider
SHSusanne Heydt
Susanne Heydt
KTKarine Tréguer
Karine Tréguer
TBThomas Boettger
Thomas Boettger
AHAnton J. G. Horrevoets
Anton J. G. Horrevoets
DBDittmar Böckler
Dittmar Böckler

6 January 2016 in Nature
Verified
Journal Article
Open access
PDF file
KWKerstin Wilhelm
Kerstin Wilhelm
KHKatharina Happel
Katharina Happel
GEGuy Eelen
Guy Eelen
SSSandra Schoors
Sandra Schoors
MOMark F. Oellerich
Mark F. Oellerich
MPMichael Potente
Michael Potente
The transcription factor FOXO1 is identified as a crucial checkpoint of vascular growth, coupling the metabolic and proliferative activities of endothelial cells. The mechanisms that balance the metabolism of endothelial cells and their growth state are not known. Here Michael Potente and colleagues identify the transcription factor FOXO1 as a crucial checkpoint of vascular growth, coupling the metabolic and proliferative activities of endothelial cells. They find that FOXO1 expression in endothelial cells is required to keep the cells quiescent, through suppressing c-MYC signalling, thereby reducing glycolysis and mitochondrial respiration. Endothelial-specific deletion of FOXO1 in mice induces vessel hyperplasia and enlargement. Endothelial cells (ECs) are plastic cells that can switch between growth states with different bioenergetic and biosynthetic requirements1. Although quiescent in most healthy tissues, ECs divide and migrate rapidly upon proangiogenic stimulation2,3. Adjusting endothelial metabolism to the growth state is central to normal vessel growth and function1,4, yet it is poorly understood at the molecular level. Here we report that the forkhead box O (FOXO) transcription factor FOXO1 is an essential regulator of vascular growth that couples metabolic and proliferative activities in ECs. Endothelial-restricted deletion of FOXO1 in mice induces a profound increase in EC proliferation that interferes with coordinated sprouting, thereby causing hyperplasia and vessel enlargement. Conversely, forced expression of FOXO1 restricts vascular expansion and leads to vessel thinning and hypobranching. We find that FOXO1 acts as a gatekeeper of endothelial quiescence, which decelerates metabolic activity by reducing glycolysis and mitochondrial respiration. Mechanistically, FOXO1 suppresses signalling by MYC (also known as c-MYC), a powerful driver of anabolic metabolism and growth5,6. MYC ablation impairs glycolysis, mitochondrial function and proliferation of ECs while its EC-specific overexpression fuels these processes. Moreover, restoration of MYC signalling in FOXO1-overexpressing endothelium normalizes metabolic activity and branching behaviour. Our findings identify FOXO1 as a critical rheostat of vascular expansion and define the FOXO1–MYC transcriptional network as a novel metabolic checkpoint during endothelial growth and proliferation.

1 September 2009 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TBThomas Boettger
Thomas Boettger
NBNadine Beetz
Nadine Beetz
SKSawa Kostin
Sawa Kostin
JSJohanna Schneider
Johanna Schneider
MKMarcus Krüger
Marcus Krüger
TBThomas Braun
Thomas Braun
VSMCs respond to changes in the local environment by adjusting their phenotype from contractile to synthetic, a phenomenon known as phenotypic modulation or switching. Failure of VSMCs to acquire and maintain the contractile phenotype plays a key role in a number of major human diseases, including arteriosclerosis. Although several regulatory circuits that control differentiation of SMCs have been identified, the decisive mechanisms that govern phenotypic modulation remain unknown. Here, we demonstrate that the mouse miR-143/145 cluster, expression of which is confined to SMCs during development, is required for VSMC acquisition of the contractile phenotype. VSMCs from miR-143/145–deficient mice were locked in the synthetic state, which incapacitated their contractile abilities and favored neointimal lesion development. Unbiased high-throughput, quantitative, mass spectrometry–based proteomics using reference mice labeled with stable isotopes allowed identification of miR-143/145 targets; these included angiotensin-converting enzyme (ACE), which might affect both the synthetic phenotype and contractile functions of VSMCs. Pharmacological inhibition of either ACE or the AT1 receptor partially reversed vascular dysfunction and normalized gene expression in miR-143/145–deficient mice. We conclude that manipulation of miR-143/145 expression may offer a new approach for influencing vascular repair and attenuating arteriosclerotic pathogenesis.

28 March 2008 in Circulation Research
Verified
Journal Article
Closed access
PDF file
OVOlesya Vakhrusheva
Olesya Vakhrusheva
CSChristian Smolka
Christian Smolka
PGPraveen Gajawada
Praveen Gajawada
SKSawa Kostin
Sawa Kostin
TBThomas Boettger
Thomas Boettger
EBEva Bober
Eva Bober
Sirt7 is a member of the mammalian sirtuin family consisting of 7 genes, Sirt1 to Sirt7, which all share a homology to the founding family member, the yeast Sir2 gene. Most sirtuins are supposed to act as histone/protein deacetylases, which use oxidized NAD in a sirtuin-specific, 2-step deacetylation reaction. To begin to decipher the biological role of Sirt7, we inactivated the Sirt7 gene in mice. Sirt7-deficient animals undergo a reduction in mean and maximum lifespans and develop heart hypertrophy and inflammatory cardiomyopathy. Sirt7 mutant hearts are also characterized by an extensive fibrosis, which leads to a 3-fold increase in collagen III accumulation. We found that Sirt7 interacts with p53 and efficiently deacetylates p53 in vitro, which corresponds to hyperacetylation of p53 in vivo and an increased rate of apoptosis in the myocardium of mutant mice. Sirt7-deficient primary cardiomyocytes show a ≈200% increase in basal apoptosis and a significantly diminished resistance to oxidative and genotoxic stress suggesting a critical role of Sirt7 in the regulation of stress responses and cell death in the heart. We propose that enhanced activation of p53 by lack of Sirt7-mediated deacetylation contributes to the heart phenotype of Sirt7 mutant mice.

29 November 2001 in Nature
Verified
Journal Article
Closed access
PDF file
Raúl EstévezRaúl Estévez
Raúl Estévez
TBThomas Boettger
Thomas Boettger
VSValentin Stein
Valentin Stein
RBRalf Birkenhäger
Ralf Birkenhäger
EOEdgar Otto
Edgar Otto
TJThomas J. Jentsch
Thomas J. Jentsch

1 April 2002 in Nature
Verified
Journal Article
Closed access
PDF file
TBThomas Boettger
Thomas Boettger
CHChristian A. Hübner
Christian A. Hübner
HMHannes Maier
Hannes Maier
MRMarco B. Rust
Marco B. Rust
FBFranz X. Beck
Franz X. Beck
TJThomas J. Jentsch
Thomas J. Jentsch